David Huang

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Donia M Moujalled, Fiona C Brown, Giovanna Pomilio, Natasha S Anstee, Veronique Litalien, Ella R Thompson, Thomas Morley, Sarah MacRaild, Chong C Chua, SeBastien Banquet, Maia Chanrion, Ana-Leticia Maragno, Marie Schoumacher, Marco J Herold, Guillaume Lessene, Olivier Geneste, David CS Huang, Andrew W Roberts, Piers Blombery, Andrew Wei

Conference Proceedings  |  2020  |  BLOOD

Background: Recent randomized trials have demonstrated improvements in overall survival (OS) for the BCL-2 inhibito..

BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic

Victor S Lin, Zhuo-Fan Xu, David CS Huang, Rachel Thijssen

Journal article  |  2020  |  CANCERS

The discovery of the link between defective apoptotic regulation and cancer cell survival engendered the idea of targeting aberran..

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds

Ming-Jie Luo, Michelle Palmieri, Chris D Riffkin, Anuratha Sakthianandeswaren, Tirta Mario Djajawi, Yumiko Hirokawa, Victoria Shuttleworth, David H Segal, Christine A White, Duong Nhu, Guillaume Lessene, Margaret Lee, Peter Gibbs, David CS Huang, Oliver M Sieber, Jia-nan Gong

Journal article  |  2020  |  CELL DEATH & DISEASE

Novel targets are required to improve the outcomes for patients with colorectal cancers. In this regard, the selective inhibitor o..

Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Donia M Moujalled, Diane T Hanna, Soroor Hediyeh-zadeh, Giovanna Pomilio, Lauren Brown, Veronique Litalien, Ray Bartolo, Shaun Fleming, Maia Chanrion, Sebastien Banquet, Ana-Leticia Maragno, Laurence Kraus-Berthier, Marie Schoumacher, Charles G Mullighan, Angela Georgiou, Christine A White, Guillaume Lessene, David CS Huang, Andrew W Roberts, Olivier Geneste, et al.

Journal article  |  2020  |  BLOOD ADVANCES

Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains a clinical challenge. Relapsed disease ha..

Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells

Rachel Thijssen, Silvia Alvarez-Diaz, Clea Grace, Ming-yuan Gao, David H Segal, Zhen Xu, Andreas Strasser, David CS Huang

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins

Leah Fitzsimmons, Rachel Cartlidge, Catherine Chang, Nenad Sejic, Laura CA Galbraith, Chathura D Suraweera, Deborah Croom-Carter, Grant Dewson, Rosemary J Tierney, Andrew Bell, Clare Shannon-Lowe, Marco J Herold, Alan B Rickinson, Peter M Colman, David CS Huang, Andreas Strasser, Marc Kvansakul, Martin Rowe, Gemma L Kelly

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

Epstein-Barr virus (EBV), which is ubiquitous in the adult population, is causally associated with human malignancies. Like many i..

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, R Thijssen, G Pomilio, A Ivey, JM Salmon, C Glytsou, SA Fleming, Q Zhang, H Ma, KP Patel, SM Kornblau, Z Xu, CC Chua, Xufeng Chen, P Blombery, et al.

Journal article  |  2020  |  BLOOD

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for..

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Piers Blombery, Ella R Thompson, Nguyen Tamia, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F Seymour, David A Westerman, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2020  |  BLOOD

The BCL2 inhibitor venetoclax has complete response rates of up to 50% in chronic lymphocytic leukemia patients, but secondary res..

MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex

Tirta Mario Djajawi, Lei Liu, Jia-nan Gong, Allan Shuai Huang, Ming-jie Luo, Zhen Xu, Toru Okamoto, Melissa J Call, David CS Huang, Mark F van Delft

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

MCL1, a BCL2 relative, is critical for the survival of many cells. Its turnover is often tightly controlled through both ubiquitin..

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Charis E Teh, Jia-Nan Gong, David Segal, Tania Tan, Cassandra J Vandenberg, Pasquale L Fedele, Michael SY Low, George Grigoriadis, Simon J Harrison, Andreas Strasser, Andrew W Roberts, David CS Huang, Garry P Nolan, Daniel HD Gray, Melissa E Ko

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

Multiple myeloma is an incurable and fatal cancer of immunoglobulin-secreting plasma cells. Most conventional therapies aim to ind..